Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 5/20 | 0.35 |
| ▸ | CPT2 | P23786 | 3/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.34 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934444 | 0.95 | SPHK2 (0.36) | CPT1ACPT2CPT1BSPHK2SPHK1 | |
| SCHEMBL932514 | 0.94 | DGAT1 (0.36) | CPT1ACPT2CPT1BF11BTK | |
| SCHEMBL932417 | 0.93 | CPT1A (0.33) | CPT1ACPT2CPT1BSPHK2SPHK1 | |
| SCHEMBL933350 | 0.92 | ESR2 (0.35) | CPT1ACPT2CPT1BF11HSP90AA1 | |
| SCHEMBL12661150 | 0.90 | ALDH1A1 (0.37) | — | |
| SCHEMBL1889501 | 0.89 | CPT1A (0.37) | CPT1ACPT2SPHK2SPHK1F11 | |
| SCHEMBL933906 | 0.87 | SPHK2 (0.36) | CPT1ASPHK2SPHK1F11SCD | |
| SCHEMBL932212 | 0.86 | SPHK2 (0.34) | CPT1ACPT2SPHK2SPHK1F11 | |
| SCHEMBL933654 | 0.86 | CHEK2 (0.36) | SPHK2SPHK1 | |
| SCHEMBL932607 | 0.86 | CHEK2 (0.36) | SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CPT1A 90/4885CPT2 2536/4885CPT1B 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.